2023 Junshi Biosciences reports 58% revenue increase to RMB1.5bn, with TUOYI® sales up 25% to RMB919m.

Leading Chinese biopharmaceutical company Junshi Biosciences reported a 58% increase in revenue from pharmaceutical products in 2023, reaching approximately RMB1.5 billion. Sales revenue of TUOYI® (toripalimab) increased by 25% to around RMB919 million. The company's R&D expenses decreased by 19% to RMB1.937 billion. Junshi Biosciences is developing innovative therapies and novel drugs for five major therapeutic areas, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases, and infectious diseases.

March 28, 2024
5 Articles